GW Pharmaceuticals prospers on Epidiolex trial results for rare epilepsy

28 June 2016

The UK’s GW Pharmaceuticals (LSE: GWP) has announced positive results of the first randomized, double-blind, placebo-controlled Phase III trial of Epidiolex (cannabidiol or CBD) for Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

Shares in the company, which is aimed at discovering, developing and commercializing new therapeutics derived from the cannabis plant, climbed by as much as 29% at one point on Monday following the news, before closing up 12.35%.

This trial showed that Epidiolex, when added as an adjunct to the patient’s current treatment, achieved the primary endpoint of a significant reduction in the monthly frequency of drop seizures assessed over the entire 14-week treatment period compared with placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK